Low Tau Expression in Gastric Cancer and Paclitaxel Treatment
Author Information
Author(s): Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F, Sasaki A, Inoue H, Sugimachi K, Mori M
Primary Institution: Kyushu University Hospital at Beppu
Hypothesis
Can tau expression levels in gastric cancer predict the effectiveness of Paclitaxel treatment?
Conclusion
Low tau expression in gastric cancer patients is associated with a favorable response to Paclitaxel treatment.
Supporting Evidence
- All six cases of low tau expression showed a favorable response to Paclitaxel treatment.
- Twelve out of fourteen cases with high tau expression showed no response to the treatment.
- The serum CEA values decreased significantly in tau-negative cases after treatment.
Takeaway
If a patient with gastric cancer has low tau levels, they are more likely to respond well to a drug called Paclitaxel.
Methodology
The study examined tissue specimens from 20 gastric cancer patients and evaluated their response to Paclitaxel treatment based on tau expression levels.
Limitations
The study had a small sample size and focused only on advanced and nonresectable gastric cancer cases.
Participant Demographics
The average age of participants was 66 years, with 14 males and 6 females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website